Agilent Technologies has unveiled the Altura Ultra Inert HPLC Columns, a next-generation solution tailored for lab managers overseeing biopharmaceutical development and QA/QC operations. Built for precision, speed, and robustness, these columns offer an effective tool for navigating the challenges of modern biotherapeutic testing.
With a sharp focus on performance, the Altura columns offer:
- Up to 2x greater sensitivity
- Up to 3x higher signal-to-noise ratios
- Optimized separation of challenging analytes
Their release marks a strategic expansion of Agilent’s inert LC technologies, reinforcing the company’s leadership in analytical innovation.
Designed for Biopharma Lab Efficiency
According to David Edwards, Agilent's VP and general manager of the Chemistries and Supplies Division, "Customers producing complex therapeutics are under growing pressure to detect and characterize impurities with greater precision... Altura reflects our commitment to help customers reach new heights in analytical performance and scientific discovery."
For lab managers balancing compliance and performance, the Altura columns are ideal for:
- Peptide GLP-1 drug testing
- Oligonucleotide assay workflows
- High-sensitivity impurity profiling
Real-World Application Validated
Piotr Alvarez, senior scientist at RIC Group, highlighted the operational improvements: "The Altura HILIC-Z HPLC column substantially reduced the undesired analyte-surface interactions in the analysis of GLP-1 receptor agonist drug products... at least a 30 percent increase in sensitivity and reduction in peak tailing."
This release exemplifies Agilent's mission to empower labs with cutting-edge tools that simplify complex workflows while meeting regulatory expectations.
